These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26510944)

  • 1. Cariprazine: First Global Approval.
    McCormack PL
    Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of cariprazine.
    Stahl SM
    CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders.
    De Berardis D; Orsolini L; Iasevoli F; Prinzivalli E; de Bartolomeis A; Serroni N; Mazza M; Valchera A; Fornaro M; Vecchiotti R; Carano A; Sepede G; Vellante F; Matarazzo I; Pompili M; Perna G; Conti C; Segura-García C; Martinotti G; Di Giannantonio M
    Curr Pharm Des; 2016; 22(33):5144-5162. PubMed ID: 27396597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of cariprazine in the treatment of bipolar disorder.
    Saraf G; Pinto JV; Yatham LN
    Expert Opin Pharmacother; 2019 Dec; 20(17):2063-2072. PubMed ID: 31644326
    [No Abstract]   [Full Text] [Related]  

  • 9. Cariprazine for the Treatment of Bipolar Disorder.
    Findlay LJ; El-Mallakh PL; El-Mallakh RS
    Perspect Psychiatr Care; 2017 Jul; 53(3):148-155. PubMed ID: 27059102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential.
    Koziej S; Kowalczyk E; Soroka E
    Med Sci Monit; 2024 Sep; 30():e945411. PubMed ID: 39300746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
    Veselinović T; Paulzen M; Gründer G
    Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms].
    Laszlovszky I; Kiss B; Barabassy A; Kapas M; Nemeth G
    Neuropsychopharmacol Hung; 2019 Sep; 21(3):103-118. PubMed ID: 31537751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
    Lao KS; He Y; Wong IC; Besag FM; Chan EW
    CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.
    Earley W; Burgess MV; Rekeda L; Dickinson R; Szatmári B; Németh G; McIntyre RS; Sachs GS; Yatham LN
    Am J Psychiatry; 2019 Jun; 176(6):439-448. PubMed ID: 30845817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis.
    Durgam S; Earley W; Lu K; Németh G; Laszlovszky I; Volk S; Litman RE
    Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29119668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical potential of cariprazine in the treatment of acute mania.
    Altınbaş K; Guloksuz S; Oral ET
    Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.
    Kane JM; Zukin S; Wang Y; Lu K; Ruth A; Nagy K; Laszlovszky I; Durgam S
    J Clin Psychopharmacol; 2015 Aug; 35(4):367-73. PubMed ID: 26075487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.